COPD For Patient Lectures By Randa Abdelal, PharmD

Loading...

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

0 comments

Post a comment

    Post a comment
    Embed Video
    Edit your comment Cancel

    Favorites, Groups & Events

    COPD For Patient Lectures By Randa Abdelal, PharmD - Presentation Transcript

    1. Dr. Randa Yehia-Abdelal Pharm D Clinical Pharmacist At Muhlenberg Regional Medical Center COPD & Asthma
    2. Facts About COPD
      • Cigarette smoking is the primary Cause of COPD.
      • The WHO estimates 1.1 billion smoker
      • worldwide, increasing to 1.6 billion by
      • 2025 in low&middle-income countries.
      • In 2000,the WHO estimated 2.74 million
      • deaths worldwide from COPD.
      • In 1990 ,COPD was ranked 12 th as burden
      • of disease,by 2020 it is projected to rank 5th
    3. Burden Of COPD
      • Most epidemiological studies have found that COPD
      • prevalence,morbidity and mortality increase over
      • time and are greater in men than in women.
      • COPD prevalence is directly related to prevalence
      • of smoking.
      • Very few studies have quantified the economic
      • and social burden of COPD and its quality of life.
      • Directed costs of COPD are substantial in
      • developed countries while indirect cost are
      • important in developing countries.
    4. GOLD Definition : COPD i s a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases Chronic Obstructive Pulmonary Disease ( COPD ) This definition does not use the terms chronic bronchitis and emphysema and excludes asthma (reversible airflow limitation). and associated with systemic manifestations.
    5. Chronic Obstructive Pulmonary Disease ( COPD ) Chronic bronchitis Defined as the presence of cough and sputum production for at least 3 months in each of 2 consecutive years, is not necessarily associated with airflow limitation. Emphysema Defined as destruction of the alveoli, is a pathological term that is sometimes (incorrectly) used clinically.
    6. Diagnosis Of COPD The diagnosis should be confirmed by Spirometry   Indicators for Considering a COPD Diagnosis Chronic cough Present intermittently or every day. Often present throughout the day; seldom only nocturnal. Chronic sputum production Any pattern of chronic sputum production may indicate COPD. Acute bronchitis Repeated episodes. Dyspnea that is Progressive (worsens over time). Persistent (present every day). Worse on exercise. Worse during respiratory infections. History of exposure to risk factors Tobacco smoke … . (including popular local preparations). Occupational dusts and chemicals. Smoke from home cooking and heating fuel.
    7. Role of Inflammation in COPD Small airway disease Parenchymal destruction Airflow Limitation Inflammation
    8. Asthma
      • Onset in mid-life.
      • Symptoms slowly progressive.
      • Long smoking history.
      • Dyspnea during exercise.
      • Largely irreversible airflow limitation.
      • Onset early in life (often childhood). .Symptoms vary from day to day. .Symptoms at night/early morning. .Allergy, rhinitis, and/or eczema also present. .Family history of asthma. .Largely reversible airflow limitation.
      COPD ASTHMA & COPD COPD Asthma
      • Prevent disease progression .
      • Relieve symptoms.
      • Improve exercise tolerance.
      • Improve health status.
      • Prevent and treat complications.
      • Prevent and treat exacerbations.
      • Reduce mortality.
      • Prevent or minimize side effects from treatment.
      Goals of COPD management
        • 1. Assess and Monitor Disease 2. Reduce Risk Factors 3. Manage Stable COPD 4. Manage Acute Exacerbations
      COPD FOUR COMPONENT MANAGEMENT PROGRAM
      • A detailed medical history.
      • Spirometry.
      • Bronchodilator reversibility testing.
      • Inhaled glucocorticosteroid trial
      • (6 weeks to 3 months).
      • Chest X-ray.
      • Arterial blood gas measurement.
      • Alpha-1 antitrypsin deficiency screening.
      Assess and Monitor Disease
      • Smoking cessation is the single most effective
      • And cost-effective - intervention to reduce the
      • risk of developing COPD and slow its progression.
      • Smoking Prevention
      • Avoid occupational Exposures
      Reduce Risk Factors
      • Patient education.
      • Pharmacologic Treatment.
      • - Bronchodilators,
      • - Glucocorticosteroids,
      • - Vaccines,
      • - Antibiotics,
      • - Mucolytic
      • - Antitussives,
      • - Respiratory Stimulants
      • Non-Pharmacologic Treatment
      • - Rehabilitation,
      • - Oxygen Therapy,
      • - Surgical Treatments(Bullectomy,LVRS,L.T)
      Management of stable COPD
    9. X
    10. . Marked increase in intensity of symptoms, such as sudden development of resting dyspnea
      • Newly occuring arrhythmias
      . Diagnostic uncertainty . Older age
      • Insufficient home support
      • Failure of exacerbation to respond to initial medical management
      Indications for Hospital Admission for Acute Exacerbations
      • Onset of new physical signs (e.g.,cyanosis, peripheral edema)
        • Severe background COPD
    11. Quality Of Life
      • .
      • Survival figures for COPD are worse , COPD patients are often stranded at home with little support &suffered from depression.
      • In contrast
      • lung cancer sufferers have access to a wide network of support such
      • as palliative care services, and have lower depression
      Importance of Quality Of Life In Patients With COPD 50 patients with inoperable lung cancer Vs 50 with severe COPD All >60y, were questioned about their quality of life. 80%of COPD patients were housebound , with 36% largely confined to a chair. In comparison 36% of lung cancer patients were housebound, only 10% chair-bound
      • One study in UK examined whether COPD patients were relatively
      • disadvantaged in terms of medical and social care compared with
      • a group with inoperable lung cancer.
      • Conclusion: This study suggests that :
      • patients with end stage COPD have significantly impaired quality of
      • life and emotional well being which may not be as well met as those
      • of patients with lung cancer, .
      • COPD patients palliative care needs remain unaddressed
      Importance of Quality Of Life In Patients With COPD
    12. Thank you
    13.  

    + Randa AbdelalRanda Abdelal, 7 months ago

    custom

    714 views, 0 favs, 0 embeds more stats

    COPD For Patient Lectures By Randa Abdelal, PharmD

    More info about this document

    © All Rights Reserved

    Go to text version

    • Total Views 714
      • 714 on SlideShare
      • 0 from embeds
    • Comments 0
    • Favorites 0
    • Downloads 58
    Most viewed embeds

    more

    All embeds

    less

    Flagged as inappropriate Flag as inappropriate
    Flag as inappropriate

    Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details.

    Cancel
    File a copyright complaint
    Having problems? Go to our helpdesk?

    Categories